Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease. / Hedegaard, Berit Storgaard; Bork, Christian Sørensen; Kaltoft, Morten; Klausen, Ib Christian; Schmidt, Erik Berg; Kamstrup, Pia Rørbæk; Langsted, Anne; Nordestgaard, Børge Grønne.

I: Journal of the American College of Cardiology, Bind 80, Nr. 21, 2022, s. 1998-2010.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Hedegaard, BS, Bork, CS, Kaltoft, M, Klausen, IC, Schmidt, EB, Kamstrup, PR, Langsted, A & Nordestgaard, BG 2022, 'Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease', Journal of the American College of Cardiology, bind 80, nr. 21, s. 1998-2010. https://doi.org/10.1016/j.jacc.2022.09.021

APA

Hedegaard, B. S., Bork, C. S., Kaltoft, M., Klausen, I. C., Schmidt, E. B., Kamstrup, P. R., Langsted, A., & Nordestgaard, B. G. (2022). Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 80(21), 1998-2010. https://doi.org/10.1016/j.jacc.2022.09.021

Vancouver

Hedegaard BS, Bork CS, Kaltoft M, Klausen IC, Schmidt EB, Kamstrup PR o.a. Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology. 2022;80(21):1998-2010. https://doi.org/10.1016/j.jacc.2022.09.021

Author

Hedegaard, Berit Storgaard ; Bork, Christian Sørensen ; Kaltoft, Morten ; Klausen, Ib Christian ; Schmidt, Erik Berg ; Kamstrup, Pia Rørbæk ; Langsted, Anne ; Nordestgaard, Børge Grønne. / Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease. I: Journal of the American College of Cardiology. 2022 ; Bind 80, Nr. 21. s. 1998-2010.

Bibtex

@article{72d2b68cb34e46b1a218392be70fbf88,
title = "Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease",
abstract = "Background: Genetically elevated plasma lipoprotein(a) and familial hypercholesterolemia each result in premature atherosclerotic cardiovascular disease (ASCVD); however, a direct comparison in the same population is needed of these 2 genetic traits on the risk of ASCVD. Objectives: We determined the level of plasma lipoprotein(a) that is equivalent to low-density lipoprotein (LDL) cholesterol in clinically and genetically diagnosed familial hypercholesterolemia on risk of myocardial infarction and ASCVD. Methods: We examined the CGPS (Copenhagen General Population Study) with determination of lipoprotein(a) and familial hypercholesterolemia in 69,644 individuals followed for 42 years, during which time, 4,166 developed myocardial infarction and 11,464, ASCVD. Results: For risk of myocardial infarction, the plasma lipoprotein(a) level equivalent to LDL cholesterol in clinical familial hypercholesterolemia was 67 mg/dL (142 nmol/L) for MEDPED (Make Early Diagnosis to Prevent Early Death), 110 mg/dL (236 nmol/L) for Simon Broome, 256 mg/dL (554 nmol/L) for possible DLCN (Dutch Lipid Clinic Network), and 402 mg/dL (873 nmol/L) for probable+definite DLCN, whereas it was 180 mg/dL (389 nmol/L) for genetic familial hypercholesterolemia. Corresponding values for ASCVD were 130 mg/dL (280 nmol/L), 150 mg/dL (323 nmol/L), 227 mg/dL (491 nmol/L), 391 mg/dL (849 nmol/L), and 175 mg/dL (378 nmol/L), respectively. Individuals with both elevated lipoprotein(a) and either familial hypercholesterolemia or a family history of premature myocardial infarction had a higher risk of myocardial infarction and ASCVD compared with individuals with only 1 of these genetic traits, with the highest HRs being for lipoprotein(a) upper 20% vs lower 50% of 14.0 (95% CI: 9.15-21.3) for myocardial infarction and 5.05 (95% CI: 3.41-7.48) for ASCVD. Conclusions: Lipoprotein(a) levels equivalent to LDL cholesterol in clinical and genetic familial hypercholesterolemia were 67 to 402 mg/dL and 180 mg/dL, respectively, for myocardial infarction and 130 to 391 mg/dL and 175 mg/dL, respectively, for ASCVD.",
keywords = "cardiovascular disease, genetic FH, LDL cholesterol, Lp(a), myocardial infarction, premature familial myocardial infarction",
author = "Hedegaard, {Berit Storgaard} and Bork, {Christian S{\o}rensen} and Morten Kaltoft and Klausen, {Ib Christian} and Schmidt, {Erik Berg} and Kamstrup, {Pia R{\o}rb{\ae}k} and Anne Langsted and Nordestgaard, {B{\o}rge Gr{\o}nne}",
note = "Publisher Copyright: {\textcopyright} 2022 American College of Cardiology Foundation",
year = "2022",
doi = "10.1016/j.jacc.2022.09.021",
language = "English",
volume = "80",
pages = "1998--2010",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier",
number = "21",

}

RIS

TY - JOUR

T1 - Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease

AU - Hedegaard, Berit Storgaard

AU - Bork, Christian Sørensen

AU - Kaltoft, Morten

AU - Klausen, Ib Christian

AU - Schmidt, Erik Berg

AU - Kamstrup, Pia Rørbæk

AU - Langsted, Anne

AU - Nordestgaard, Børge Grønne

N1 - Publisher Copyright: © 2022 American College of Cardiology Foundation

PY - 2022

Y1 - 2022

N2 - Background: Genetically elevated plasma lipoprotein(a) and familial hypercholesterolemia each result in premature atherosclerotic cardiovascular disease (ASCVD); however, a direct comparison in the same population is needed of these 2 genetic traits on the risk of ASCVD. Objectives: We determined the level of plasma lipoprotein(a) that is equivalent to low-density lipoprotein (LDL) cholesterol in clinically and genetically diagnosed familial hypercholesterolemia on risk of myocardial infarction and ASCVD. Methods: We examined the CGPS (Copenhagen General Population Study) with determination of lipoprotein(a) and familial hypercholesterolemia in 69,644 individuals followed for 42 years, during which time, 4,166 developed myocardial infarction and 11,464, ASCVD. Results: For risk of myocardial infarction, the plasma lipoprotein(a) level equivalent to LDL cholesterol in clinical familial hypercholesterolemia was 67 mg/dL (142 nmol/L) for MEDPED (Make Early Diagnosis to Prevent Early Death), 110 mg/dL (236 nmol/L) for Simon Broome, 256 mg/dL (554 nmol/L) for possible DLCN (Dutch Lipid Clinic Network), and 402 mg/dL (873 nmol/L) for probable+definite DLCN, whereas it was 180 mg/dL (389 nmol/L) for genetic familial hypercholesterolemia. Corresponding values for ASCVD were 130 mg/dL (280 nmol/L), 150 mg/dL (323 nmol/L), 227 mg/dL (491 nmol/L), 391 mg/dL (849 nmol/L), and 175 mg/dL (378 nmol/L), respectively. Individuals with both elevated lipoprotein(a) and either familial hypercholesterolemia or a family history of premature myocardial infarction had a higher risk of myocardial infarction and ASCVD compared with individuals with only 1 of these genetic traits, with the highest HRs being for lipoprotein(a) upper 20% vs lower 50% of 14.0 (95% CI: 9.15-21.3) for myocardial infarction and 5.05 (95% CI: 3.41-7.48) for ASCVD. Conclusions: Lipoprotein(a) levels equivalent to LDL cholesterol in clinical and genetic familial hypercholesterolemia were 67 to 402 mg/dL and 180 mg/dL, respectively, for myocardial infarction and 130 to 391 mg/dL and 175 mg/dL, respectively, for ASCVD.

AB - Background: Genetically elevated plasma lipoprotein(a) and familial hypercholesterolemia each result in premature atherosclerotic cardiovascular disease (ASCVD); however, a direct comparison in the same population is needed of these 2 genetic traits on the risk of ASCVD. Objectives: We determined the level of plasma lipoprotein(a) that is equivalent to low-density lipoprotein (LDL) cholesterol in clinically and genetically diagnosed familial hypercholesterolemia on risk of myocardial infarction and ASCVD. Methods: We examined the CGPS (Copenhagen General Population Study) with determination of lipoprotein(a) and familial hypercholesterolemia in 69,644 individuals followed for 42 years, during which time, 4,166 developed myocardial infarction and 11,464, ASCVD. Results: For risk of myocardial infarction, the plasma lipoprotein(a) level equivalent to LDL cholesterol in clinical familial hypercholesterolemia was 67 mg/dL (142 nmol/L) for MEDPED (Make Early Diagnosis to Prevent Early Death), 110 mg/dL (236 nmol/L) for Simon Broome, 256 mg/dL (554 nmol/L) for possible DLCN (Dutch Lipid Clinic Network), and 402 mg/dL (873 nmol/L) for probable+definite DLCN, whereas it was 180 mg/dL (389 nmol/L) for genetic familial hypercholesterolemia. Corresponding values for ASCVD were 130 mg/dL (280 nmol/L), 150 mg/dL (323 nmol/L), 227 mg/dL (491 nmol/L), 391 mg/dL (849 nmol/L), and 175 mg/dL (378 nmol/L), respectively. Individuals with both elevated lipoprotein(a) and either familial hypercholesterolemia or a family history of premature myocardial infarction had a higher risk of myocardial infarction and ASCVD compared with individuals with only 1 of these genetic traits, with the highest HRs being for lipoprotein(a) upper 20% vs lower 50% of 14.0 (95% CI: 9.15-21.3) for myocardial infarction and 5.05 (95% CI: 3.41-7.48) for ASCVD. Conclusions: Lipoprotein(a) levels equivalent to LDL cholesterol in clinical and genetic familial hypercholesterolemia were 67 to 402 mg/dL and 180 mg/dL, respectively, for myocardial infarction and 130 to 391 mg/dL and 175 mg/dL, respectively, for ASCVD.

KW - cardiovascular disease

KW - genetic FH

KW - LDL cholesterol

KW - Lp(a)

KW - myocardial infarction

KW - premature familial myocardial infarction

U2 - 10.1016/j.jacc.2022.09.021

DO - 10.1016/j.jacc.2022.09.021

M3 - Journal article

C2 - 36396201

AN - SCOPUS:85141289408

VL - 80

SP - 1998

EP - 2010

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 21

ER -

ID: 329590075